

Heinz Wiendl

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9245284/heinz-wiendl-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

436
papers

15,473
citations

65
h-index

101
g-index

462
ext. papers

18,823
ext. citations

7.2
avg, IF

6.6
L-index

#	Paper	IF	Citations
436	Neuropsychological Performance in Autoimmune Limbic Encephalitis: Evidence from an Immunotherapy-Naïve Cohort.. <i>Archives of Clinical Neuropsychology</i> , 2022 ,	2.7	1
435	How patients with multiple sclerosis acquire disability.. <i>Brain</i> , 2022 ,	11.2	10
434	Bilaterality of temporal EEG findings in limbic encephalitis compared to other mesiotemporal epilepsies - A retrospective cohort study.. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2022 , 96, 98-101	3.2	
433	Effect of desire for pregnancy on decisions to escalate treatment in multiple sclerosis care: Differences between MS specialists and non-MS specialists.. <i>Multiple Sclerosis and Related Disorders</i> , 2022 , 57, 103389	4	1
432	Vaccine Response in Patients With Multiple Sclerosis Receiving Teriflunomide.. <i>Frontiers in Neurology</i> , 2022 , 13, 828616	4.1	0
431	Stroke induces disease-specific myeloid cells in the brain parenchyma and pia.. <i>Nature Communications</i> , 2022 , 13, 945	17.4	0
430	The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021.. <i>Multiple Sclerosis Journal</i> , 2022 , 13524585211069068	5	1
429	Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years.. <i>Multiple Sclerosis Journal</i> , 2022 , 13524585221079731	5	0
428	Eculizumab versus rituximab in generalised myasthenia gravis.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022 ,	5.5	1
427	Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial.. <i>Lancet Neurology</i> , 2022 ,	24.1	4
426	Blockade of inhibitory killer cell immunoglobulin-like receptors and IL-2 triggering reverses the functional hypoactivity of tumor-derived NK-cells in glioblastomas.. <i>Scientific Reports</i> , 2022 , 12, 6769	4.9	2
425	023 Relapse outcomes with natalizumab Q4W vs switch to Q6W. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022 , 93, A20.3-A21	5.5	
424	Long-Term Sonographical Follow-Up of Arterial Stenosis Due to Spontaneous Cervical Artery Dissection.. <i>Frontiers in Neurology</i> , 2021 , 12, 792321	4.1	1
423	Evaluation of Age-Dependent Immune Signatures in Patients With Multiple Sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021 , 8,	9.1	6
422	Efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis with suboptimal response to prior disease-modifying therapies: A primary analysis from the phase 3b CASTING single-arm, open-label trial. <i>European Journal of Neurology</i> , 2021 ,	6	2
421	Expert opinion on COVID-19 vaccination and the use of cladribine tablets in clinical practice.. <i>Therapeutic Advances in Neurological Disorders</i> , 2021 , 14, 17562864211058298	6.6	1
420	Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study. <i>Multiple Sclerosis Journal</i> , 2021 , 13524585211044479	5	6

419	K18.1 translates T cell receptor signals into thymic regulatory T cell development. <i>Cell Research</i> , 2021 ,	24.7	3
418	CT Hypoperfusion-Hypodensity Mismatch to Identify Patients With Acute Ischemic Stroke Within 4.5 Hours of Symptom Onset. <i>Neurology</i> , 2021 , 97, e2088-e2095	6.5	1
417	Sunlight exposure exerts immunomodulatory effects to reduce multiple sclerosis severity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021 , 118,	11.5	17
416	High anti-JCPyV serum titers coincide with high CSF cell counts in RRMS patients. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 1491-1496	5	3
415	Impact of previous disease-modifying treatment on effectiveness and safety outcomes, among patients with multiple sclerosis treated with alemtuzumab. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021 , 92, 1007-1013	5.5	11
414	Predictors, outcome and characteristics of oropharyngeal dysphagia in idiopathic inflammatory myopathy. <i>Muscle and Nerve</i> , 2021 , 63, 874-880	3.4	2
413	Zilucoplan: An Investigational Complement C5 Inhibitor for the Treatment of Acetylcholine Receptor Autoantibody-Positive Generalized Myasthenia Gravis. <i>Expert Opinion on Investigational Drugs</i> , 2021 , 30, 483-493	5.9	10
412	Dietary conjugated linoleic acid links reduced intestinal inflammation to amelioration of CNS autoimmunity. <i>Brain</i> , 2021 , 144, 1152-1166	11.2	6
411	Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus. <i>Journal of Neurology</i> , 2021 , 268, 3961-3968	5.5	26
410	Classification of neurological diseases using multi-dimensional CSF analysis. <i>Brain</i> , 2021 , 144, 2625-2634	11.2	6
409	The Innate Immune Response Characterizes Posterior Reversible Encephalopathy Syndrome. <i>Journal of Clinical Immunology</i> , 2021 , 41, 1229-1240	5.7	1
408	Characterization of Extracranial Giant Cell Arteritis with Intracranial Involvement and its Rapidly Progressive Subtype. <i>Annals of Neurology</i> , 2021 , 90, 118-129	9.4	2
407	Fundamental mechanistic insights from rare but paradigmatic neuroimmunological diseases. <i>Nature Reviews Neurology</i> , 2021 , 17, 433-447	15	4
406	Effectiveness and safety of cladribine in MS: Real-world experience from two tertiary centres. <i>Multiple Sclerosis Journal</i> , 2021 , 13524585211012227	5	9
405	Fc-Receptor Targeted Therapies for the Treatment of. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	1
404	Occurrence of status epilepticus in persons with epilepsy is determined by sex, epilepsy classification, and etiology: a single center cohort study. <i>Journal of Neurology</i> , 2021 , 268, 4816-4823	5.5	1
403	Confirmed 6-Month Disability Improvement and Worsening Correlate with Long-term Disability Outcomes in Alemtuzumab-Treated Patients with Multiple Sclerosis: Post Hoc Analysis of the CARE-MS Studies. <i>Neurology and Therapy</i> , 2021 , 10, 803-818	4.6	0
402	Failed, Interrupted, or Inconclusive Trials on Neuroprotective and Neuroregenerative Treatment Strategies in Multiple Sclerosis: Update 2015-2020. <i>Drugs</i> , 2021 , 81, 1031-1063	12.1	7

401	Kommentar der Multiple Sklerose Therapie Konsensus Gruppe (MSTKG) zur S2k-Leitlinie Multiple Sklerose. <i>DGNeurologie</i> , 2021 , 4, 319-326	0.2	0
400	Determinants of cognition in autoimmune limbic encephalitis-A retrospective cohort study. <i>Hippocampus</i> , 2021 , 31, 1092-1103	3.5	0
399	Clinical outcomes in patients who discontinue natalizumab therapy after 2 years in the Tysabri Observational Program (TOP). <i>Multiple Sclerosis Journal</i> , 2021 , 27, 410-419	5	5
398	Real-world disability improvement in patients with relapsing-remitting multiple sclerosis treated with natalizumab in the Tysabri Observational Program. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 719-728	5	4
397	Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension. <i>Neurology</i> , 2021 , 96, e610-e618	6.5	16
396	Patients with a relapsing course of steroid-responsive encephalopathy associated with autoimmune thyroiditis exhibit persistent intrathecal CD4+ T-cell activation. <i>European Journal of Neurology</i> , 2021 , 28, 1284-1291	6	0
395	Dysphagia in neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody disease as a surrogate of brain involvement?. <i>European Journal of Neurology</i> , 2021 , 28, 1765-1770	6	2
394	Neurological Manifestations of COVID-19 Feature T Cell Exhaustion and Dedifferentiated Monocytes in Cerebrospinal Fluid. <i>Immunity</i> , 2021 , 54, 164-175.e6	32.3	51
393	Chances and Challenges of Registry-Based Pharmacovigilance in Multiple Sclerosis: Lessons Learnt from the Implementation of the Multicenter REGIMS Registry. <i>Drug Safety</i> , 2021 , 44, 7-15	5.1	2
392	Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper). <i>Therapeutic Advances in Neurological Disorders</i> , 2021 , 14, 17562864211039648	6.6	13
391	Detecting myasthenia gravis as a cause of unclear dysphagia with an endoscopic tensilon test. <i>Therapeutic Advances in Neurological Disorders</i> , 2021 , 14, 17562864211035544	6.6	1
390	Vaccination in multiple sclerosis patients treated with highly effective disease-modifying drugs: an overview with consideration of cladribine tablets. <i>Therapeutic Advances in Neurological Disorders</i> , 2021 , 14, 17562864211019598	6.6	3
389	Characterisation of MS phenotypes across the age span using a novel data set integrating 34 clinical trials (NO.MS cohort): Age is a key contributor to presentation. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 2062-2076	5	10
388	Immune Cell Infiltration into the Brain After Ischemic Stroke in Humans Compared to Mice and Rats: a Systematic Review and Meta-Analysis. <i>Translational Stroke Research</i> , 2021 , 12, 976-990	7.8	12
387	Teriflunomide treatment is associated with optic nerve recovery in early multiple sclerosis. <i>Therapeutic Advances in Neurological Disorders</i> , 2021 , 14, 1756286421997372	6.6	1
386	Amyotrophic lateral sclerosis patients show increased peripheral and intrathecal T-cell activation. <i>Brain Communications</i> , 2021 , 3, fcab157	4.5	4
385	Single-cell profiling of CNS border compartment leukocytes reveals that B cells and their progenitors reside in non-diseased meninges. <i>Nature Neuroscience</i> , 2021 , 24, 1225-1234	25.5	28
384	Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021 , 8,	9.1	23

383	Multiple sclerosis therapy consensus group (MSTCG): answers to the discussion questions. <i>Neurological Research and Practice</i> , 2021 , 3, 44	3.2	3
382	Bcl6 controls meningeal Th17-B cell interaction in murine neuroinflammation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021 , 118,	11.5	1
381	Diagnostic utility of cerebrospinal fluid (CSF) findings in seizures and epilepsy with and without autoimmune-associated disease. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2021 , 91, 233-243 ^{3.2}		1
380	Dimethyl fumarate treatment restrains the antioxidative capacity of T cells to control autoimmunity. <i>Brain</i> , 2021 , 144, 3126-3141	11.2	5
379	No evidence for loss of natalizumab effectiveness with every-6-week dosing: a propensity score-matched comparison with every-4-week dosing in patients enrolled in the Tysabri Observational Program (TOP). <i>Therapeutic Advances in Neurological Disorders</i> , 2021 , 14, 17562864211042458	6.6	2
378	Next generation antibody-based therapies in neurology.. <i>Brain</i> , 2021 ,	11.2	2
377	The STING-IFN- β Dependent Axis Is Markedly Low in Patients with Relapsing-Remitting Multiple Sclerosis. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	4
376	Response to eculizumab in patients with myasthenia gravis recently treated with chronic IVIg: a subgroup analysis of REGAIN and its open-label extension study. <i>Therapeutic Advances in Neurological Disorders</i> , 2020 , 13, 1756286420911784	6.6	6
375	Complete Epstein-Barr virus seropositivity in a large cohort of patients with early multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020 , 91, 681-686	5.5	30
374	Clinical implications of serum neurofilament in newly diagnosed MS patients: A longitudinal multicentre cohort study. <i>EBioMedicine</i> , 2020 , 56, 102807	8.8	30
373	Alemtuzumab therapy changes immunoglobulin levels in peripheral blood and CSF. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020 , 7,	9.1	16
372	Is β associated with cognitive performance in early MS?. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020 , 7,	9.1	4
371	Next-Generation Neuroimmunology: New Technologies to Understand Central Nervous System Autoimmunity. <i>Trends in Immunology</i> , 2020 , 41, 341-354	14.4	7
370	TSPO imaging-guided characterization of the immunosuppressive myeloid tumor microenvironment in patients with malignant glioma. <i>Neuro-Oncology</i> , 2020 , 22, 1030-1043	1	15
369	Generation of a Model to Predict Differentiation and Migration of Lymphocyte Subsets under Homeostatic and CNS Autoinflammatory Conditions. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	1
368	Neurological immunotherapy in the era of COVID-19 - looking for consensus in the literature. <i>Nature Reviews Neurology</i> , 2020 , 16, 493-505	15	37
367	Expert opinion on the use of cladribine tablets in clinical practice. <i>Therapeutic Advances in Neurological Disorders</i> , 2020 , 13, 1756286420935019	6.6	10
366	4-aminopyridine is not just a symptomatic therapy, it has a neuroprotective effect - No. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 1311-1312	5	1

365	Covarying patterns of white matter lesions and cortical atrophy predict progression in early MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020 , 7,	9.1	5
364	Integrated single cell analysis of blood and cerebrospinal fluid leukocytes in multiple sclerosis. <i>Nature Communications</i> , 2020 , 11, 247	17.4	110
363	Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic. <i>Journal of the Neurological Sciences</i> , 2020 , 412, 116803	3.2	81
362	Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP). <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020 , 91, 660-668	5.5	39
361	Leukocyte profiles in blood and CSF distinguish neurosarcoidosis from multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2020 , 341, 577171	3.5	7
360	Why Most Acute Stroke Studies Are Positive in Animals but Not in Patients: A Systematic Comparison of Preclinical, Early Phase, and Phase 3 Clinical Trials of Neuroprotective Agents. <i>Annals of Neurology</i> , 2020 , 87, 40-51	9.4	38
359	A case of idiopathic multicentric Castleman disease in an alemtuzumab-treated patient with MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020 , 7,	9.1	4
358	Serial position effects rapidly distinguish Alzheimer's from frontotemporal dementia. <i>Journal of Neurology</i> , 2020 , 267, 975-983	5.5	2
357	Immune reconstitution therapies: concepts for durable remission in multiple sclerosis. <i>Nature Reviews Neurology</i> , 2020 , 16, 56-62	15	43
356	Lymphocyte pharmacodynamics are not associated with autoimmunity or efficacy after alemtuzumab. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020 , 7,	9.1	23
355	Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 1866-1876	5	12
354	The Impact of Dysphagia in Myositis: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	13
353	COVID-19-associated risks and effects in myasthenia gravis (CARE-MG). <i>Lancet Neurology</i> , 2020 , 19, 970-971	24.1	45
352	Ofatumumab versus Teriflunomide in Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2020 , 383, 546-557	59.2	132
351	Failed, Interrupted, or Inconclusive Trials on Immunomodulatory Treatment Strategies in Multiple Sclerosis: Update 2015-2020. <i>BioDrugs</i> , 2020 , 34, 587-610	7.9	7
350	The Agony of Choice? Preserved Affective Decision Making in Early Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2020 , 11, 914	4.1	1
349	Author response: Prospective validation of the PML risk biomarker l-selectin and influence of natalizumab extended intervals. <i>Neurology</i> , 2020 , 95, 505	6.5	0
348	Blood and cerebrospinal fluid immune cell profiles in patients with temporal lobe epilepsy of different etiologies. <i>Epilepsia</i> , 2020 , 61, e153-e158	6.4	6

347	Immune signatures of prodromal multiple sclerosis in monozygotic twins. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020 , 117, 21546-21556	11.5	12
346	MCAM/CD146 Signaling PLC β Leads to Activation of β 1 Integrins in Memory T-Cells Resulting in Increased Brain Infiltration. <i>Frontiers in Immunology</i> , 2020 , 11, 599936	8.4	4
345	Ocrelizumab initiation in patients with MS: A multicenter observational study. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020 , 7,	9.1	19
344	Prospective validation of the PML risk biomarker I-selectin and influence of natalizumab extended intervals. <i>Neurology</i> , 2019 , 93, 550-554	6.5	11
343	Human CCR5 ^{high} effector memory cells perform CNS parenchymal immune surveillance via GZMK-mediated transendothelial diapedesis. <i>Brain</i> , 2019 , 142, 3411-3427	11.2	19
342	Resolving the cognitive clinico-radiological paradox - Microstructural degeneration of fronto-striatal-thalamic loops in early active multiple sclerosis. <i>Cortex</i> , 2019 , 121, 239-252	3.8	7
341	A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity. <i>Acta Neuropathologica</i> , 2019 , 138, 237-250	14.3	50
340	Immune Cell Profiling of the Cerebrospinal Fluid Provides Pathogenetic Insights Into Inflammatory Neuropathies. <i>Frontiers in Immunology</i> , 2019 , 10, 515	8.4	16
339	Teriflunomide treatment for multiple sclerosis modulates T cell mitochondrial respiration with affinity-dependent effects. <i>Science Translational Medicine</i> , 2019 , 11,	17.5	56
338	An Assay to Determine Mechanisms of Rapid Autoantibody-Induced Neurotransmitter Receptor Endocytosis and Vesicular Trafficking in Autoimmune Encephalitis. <i>Frontiers in Neurology</i> , 2019 , 10, 178	4.1	1
337	A fatal case of daclizumab-induced liver failure in a patient with MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019 , 6, e539	9.1	7
336	Prominent T-Cell Responses against the Acetylcholine Receptor Subunit in Myasthenia Gravis. <i>Neurology Research International</i> , 2019 , 2019, 1969068	1.7	
335	Risks and risk management in modern multiple sclerosis immunotherapeutic treatment. <i>Therapeutic Advances in Neurological Disorders</i> , 2019 , 12, 1756286419836571	6.6	50
334	Does the environment influence multiple sclerosis pathogenesis via UVB light and/or induction of vitamin D?. <i>Journal of Neuroimmunology</i> , 2019 , 329, 1-8	3.5	8
333	Pretreatment anti-thyroid autoantibodies indicate increased risk for thyroid autoimmunity secondary to alemtuzumab: A prospective cohort study. <i>EBioMedicine</i> , 2019 , 46, 381-386	8.8	8
332	EMR-integrated minimal core dataset for routine health care and multiple research settings: A case study for neuroinflammatory demyelinating diseases. <i>PLoS ONE</i> , 2019 , 14, e0223886	3.7	5
331	Impact of Fc γ R variants on the response to alemtuzumab in multiple sclerosis. <i>Annals of Clinical and Translational Neurology</i> , 2019 , 6, 2586-2594	5.3	2
330	The next-generation sphingosine-1 receptor modulator BAF312 (siponimod) improves cortical network functionality in focal autoimmune encephalomyelitis. <i>Neural Regeneration Research</i> , 2019 , 14, 1950-1960	4.5	14

329	Comparing Plasma Exchange to Escalated Methyl Prednisolone in Refractory Multiple Sclerosis Relapses. <i>Journal of Clinical Medicine</i> , 2019 , 9,	5.1	6
328	VLA-2 blockade in vivo by vatelizumab induces CD4+FoxP3+ regulatory T cells. <i>International Immunology</i> , 2019 , 31, 407-412	4.9	5
327	Tolerogenic dendritic cell-based treatment for multiple sclerosis (MS): a harmonised study protocol for two phase I clinical trials comparing intradermal and intranodal cell administration. <i>BMJ Open</i> , 2019 , 9, e030309	3	35
326	Signatures of immune reprogramming in anti-CD52 therapy of MS: markers for risk stratification and treatment response. <i>Neurological Research and Practice</i> , 2019 , 1, 40	3.2	4
325	Ineffective treatment of PML with pembrolizumab: Exhausted memory T-cell subsets as a clue?. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019 , 6, e627	9.1	28
324	CD8 T cell-mediated endotheliopathy is a targetable mechanism of neuro-inflammation in Susac syndrome. <i>Nature Communications</i> , 2019 , 10, 5779	17.4	46
323	Fulminant MS Reactivation Following Combined Fingolimod Cessation and Yellow Fever Vaccination. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	6
322	Plasma kallikrein modulates immune cell trafficking during neuroinflammation via PAR2 and bradykinin release. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019 , 116, 271-276	11.5	28
321	Efficacy and safety of alemtuzumab versus fingolimod in RRMS after natalizumab cessation. <i>Journal of Neurology</i> , 2019 , 266, 165-173	5.5	15
320	Apraxia screening predicts Alzheimer pathology in frontotemporal dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019 , 90, 562-569	5.5	6
319	Can we predict cognitive decline after initial diagnosis of multiple sclerosis? Results from the German National early MS cohort (KKNMS). <i>Journal of Neurology</i> , 2019 , 266, 386-397	5.5	19
318	Association of smoking but not HLA-DRB1*15:01, APOE or body mass index with brain atrophy in early multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019 , 25, 661-668	5	5
317	Transcriptional Repressor HIC1 Contributes to Suppressive Function of Human Induced Regulatory T Cells. <i>Cell Reports</i> , 2018 , 22, 2094-2106	10.6	34
316	Mechanisms underlying lesion development and lesion distribution in CNS autoimmunity. <i>Journal of Neurochemistry</i> , 2018 , 146, 122-132	6	20
315	Sex bias in MHC I-associated shaping of the adaptive immune system. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018 , 115, 2168-2173	11.5	28
314	ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 96-120	5	286
313	Treatment choices and neuropsychological symptoms of a large cohort of early MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018 , 5, e446	9.1	40
312	Skeletal muscle cells actively shape (auto)immune responses. <i>Autoimmunity Reviews</i> , 2018 , 17, 518-529	13.6	31

311	Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 963-973 ⁵		42
310	Efficacy of daclizumab beta versus intramuscular interferon beta-1a on disability progression across patient demographic and disease activity subgroups in DECIDE. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 1883-1891	5	2
309	Anti-JCV serology during natalizumab treatment: Review and meta-analysis of 17 independent patient cohorts analyzing anti-John Cunningham polyoma virus sero-conversion rates under natalizumab treatment and differences between technical and biological sero-converters. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 563-573	5	19
308	Circulating lymphocyte levels and relationship with infection status in patients with relapsing-remitting multiple sclerosis treated with daclizumab beta. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 1725-1736	5	2
307	Relevance of raised cerebrospinal fluid monocyte levels in patients with frontotemporal dementia. <i>Neurobiology of Aging</i> , 2018 , 62, 45-52	5.6	5
306	Amygdala enlargement and emotional responses in (autoimmune) temporal lobe epilepsy. <i>Scientific Reports</i> , 2018 , 8, 9561	4.9	10
305	Immune Cell Profiling During Switching from Natalizumab to Fingolimod Reveals Differential Effects on Systemic Immune-Regulatory Networks and on Trafficking of Non-T Cell Populations into the Cerebrospinal Fluid-Results from the ToFingo Successor Study. <i>Frontiers in Immunology</i> , 2018 , 9, 1560	8.4	17
304	Nur77 serves as a molecular brake of the metabolic switch during T cell activation to restrict autoimmunity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018 , 115, E8017-E8026	11.5	44
303	Primary angiitis of the central nervous system: diagnosis and treatment. <i>Therapeutic Advances in Neurological Disorders</i> , 2018 , 11, 1756286418785071	6.6	38
302	Discriminative power of intra-retinal layers in early multiple sclerosis using 3D OCT imaging. <i>Journal of Neurology</i> , 2018 , 265, 2284-2294	5.5	3
301	A Novel PKD1 Mutation Associated With Autosomal Dominant Kidney Disease and Cerebral Cavernous Malformation. <i>Frontiers in Neurology</i> , 2018 , 9, 383	4.1	4
300	Cerebrospinal Fluid Concentrations of Neuronal Proteins Are Reduced in Primary Angiitis of the Central Nervous System. <i>Frontiers in Neurology</i> , 2018 , 9, 407	4.1	10
299	Onconeural antigen spreading in paraneoplastic neurological disease due to small cell lung cancer. <i>Oxford Medical Case Reports</i> , 2018 , 2018, omy034	0.6	3
298	Immunophenotyping of cerebrospinal fluid cells by Chipcytometry. <i>Journal of Neuroinflammation</i> , 2018 , 15, 160	10.1	9
297	Defining mechanisms of neural plasticity after brainstem ischemia in rats. <i>Annals of Neurology</i> , 2018 , 83, 1003-1015	9.4	5
296	Time-resolved transcriptome and proteome landscape of human regulatory T cell (Treg) differentiation reveals novel regulators of FOXP3. <i>BMC Biology</i> , 2018 , 16, 47	7.3	11
295	Protective potential of dimethyl fumarate in a mouse model of thalamocortical demyelination. <i>Brain Structure and Function</i> , 2018 , 223, 3091-3106	4	10
294	Blockade of MCAM/CD146 impedes CNS infiltration of T cells over the choroid plexus. <i>Journal of Neuroinflammation</i> , 2018 , 15, 236	10.1	19

293	The Coagulation Factors Fibrinogen, Thrombin, and Factor XII in Inflammatory Disorders-A Systematic Review. <i>Frontiers in Immunology</i> , 2018 , 9, 1731	8.4	73
292	Impairment of frequency-specific responses associated with altered electrical activity patterns in auditory thalamus following focal and general demyelination. <i>Experimental Neurology</i> , 2018 , 309, 54-66	5.7	10
291	Immune cell profiling in the cerebrospinal fluid of patients with primary angiitis of the central nervous system reflects the heterogeneity of the disease. <i>Journal of Neuroimmunology</i> , 2018 , 321, 109-118	3.5	10
290	Dual action by fumaric acid esters synergistically reduces adhesion to human endothelium. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 1871-1882	5	15
289	085 Clinical outcomes were better for relapsing-remitting multiple sclerosis (RRMS) patients who remained on natalizumab compared to those who switched to oral or injectable therapies after 2 years in the tysabri [®] observational program (TOP). <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018 , 89, A34.2-A34	5.5	
288	Vitiligo after alemtuzumab treatment: Secondary autoimmunity is not all about B cells. <i>Neurology</i> , 2018 , 91, e2233-e2237	6.5	26
287	Targeting Voltage-Dependent Calcium Channels with Pregabalin Exerts a Direct Neuroprotective Effect in an Animal Model of Multiple Sclerosis. <i>NeuroSignals</i> , 2018 , 26, 77-93	1.9	12
286	Immune Cell Activation in the Cerebrospinal Fluid of Patients With Parkinson's Disease. <i>Frontiers in Neurology</i> , 2018 , 9, 1081	4.1	48
285	Dietary salt promotes ischemic brain injury and is associated with parenchymal migrasome formation. <i>PLoS ONE</i> , 2018 , 13, e0209871	3.7	11
284	Low-Frequency and Rare-Coding Variation Contributes to Multiple Sclerosis Risk. <i>Cell</i> , 2018 , 175, 1679-1687.e772	6.2	12
283	Primary B Cell Lymphoma of the CNS Mimicking Anti-LGI1 Limbic Encephalitis. <i>Frontiers in Neurology</i> , 2018 , 9, 658	4.1	3
282	Apraxia profiles-A single cognitive marker to discriminate all variants of frontotemporal lobar degeneration and Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018 , 10, 363-371	5.2	11
281	Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting. <i>Multiple Sclerosis and Related Disorders</i> , 2018 , 24, 11-19	4	12
280	Reply to Liu et al.: Haplotype matters: CD226 polymorphism as a potential trigger for impaired immune regulation in multiple sclerosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017 , 114, E908-E909	11.5	3
279	Natalizumab-associated PML: Challenges with incidence, resulting risk, and risk stratification. <i>Neurology</i> , 2017 , 88, 1197-1205	6.5	79
278	Endothelial Basement Membrane Laminin 511 Contributes to Endothelial Junctional Tightness and Thereby Inhibits Leukocyte Transmigration. <i>Cell Reports</i> , 2017 , 18, 1256-1269	10.6	74
277	NMO-Spektrum-Erkrankungen. <i>Aktuelle Neurologie</i> , 2017 , 44, 180-193		1
276	CT versus MR Techniques in the Detection of Cervical Artery Dissection. <i>Journal of Neuroimaging</i> , 2017 , 27, 607-612	2.8	26

275	NMO Spectrum Disorders. <i>Neurology International Open</i> , 2017 , 01, E36-E47		2
274	Animal models in idiopathic inflammatory myopathies: How to overcome a translational roadblock?. <i>Autoimmunity Reviews</i> , 2017 , 16, 478-494	13.6	11
273	Targeting Different Monocyte/Macrophage Subsets Has No Impact on Outcome in Experimental Stroke. <i>Stroke</i> , 2017 , 48, 1061-1069	6.7	31
272	Neurochondrin is a neuronal target antigen in autoimmune cerebellar degeneration. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017 , 4, e307	9.1	26
271	Rivaroxaban ameliorates disease course in an animal model of multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2017 , 313, 125-128	3.5	5
270	Novel pathomechanisms in inflammatory neuropathies. <i>Journal of Neuroinflammation</i> , 2017 , 14, 232	10.1	22
269	Can cognitive assessment really discriminate early stages of Alzheimer's and behavioural variant frontotemporal dementia at initial clinical presentation?. <i>Alzheimer's Research and Therapy</i> , 2017 , 9, 61	9	27
268	α -integrin receptor desaturation and disease activity return after natalizumab cessation. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017 , 4, e388	9.1	18
267	Benefit-Risk Profile of Sphingosine-1-Phosphate Receptor Modulators in Relapsing and Secondary Progressive Multiple Sclerosis. <i>Drugs</i> , 2017 , 77, 1755-1768	12.1	33
266	Distinct cognitive impairments in different disease courses of multiple sclerosis-A systematic review and meta-analysis. <i>Neuroscience and Biobehavioral Reviews</i> , 2017 , 83, 568-578	9	50
265	Cladribine - an old newcomer for pulsed immune reconstitution in MS. <i>Nature Reviews Neurology</i> , 2017 , 13, 573-574	15	25
264	Analysis of Lymphocyte Extravasation Using an In Vitro Model of the Human Blood-brain Barrier. <i>Journal of Visualized Experiments</i> , 2017 ,	1.6	2
263	Consistent efficacy of daclizumab beta across patient demographic and disease activity subgroups in patients with relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2017 , 17, 32-40	4	7
262	Distinct pattern of lesion distribution in multiple sclerosis is associated with different circulating T-helper and helper-like innate lymphoid cell subsets. <i>Multiple Sclerosis Journal</i> , 2017 , 23, 1025-1030	5	24
261	14-3-3 Proteins regulate K 5.1 surface expression on T lymphocytes. <i>Traffic</i> , 2017 , 18, 29-43	5.7	11
260	Targeting B cells in relapsing-remitting multiple sclerosis: from pathophysiology to optimal clinical management. <i>Therapeutic Advances in Neurological Disorders</i> , 2017 , 10, 51-66	6.6	49
259	The quality of cortical network function recovery depends on localization and degree of axonal demyelination. <i>Brain, Behavior, and Immunity</i> , 2017 , 59, 103-117	16.6	18
258	Targeting Ewing sarcoma with activated and GD2-specific chimeric antigen receptor-engineered human NK cells induces upregulation of immune-inhibitory HLA-G. <i>Onc Immunology</i> , 2017 , 6, e1250050	7.2	65

257	Treating refractory post-herpetic anti-methyl-d-aspartate receptor encephalitis with rituximab. <i>Oxford Medical Case Reports</i> , 2017 , 2017, omx034	0.6	4
256	Infectious risk stratification in multiple sclerosis patients receiving immunotherapy. <i>Annals of Clinical and Translational Neurology</i> , 2017 , 4, 909-914	5.3	7
255	NMDAR encephalitis: passive transfer from man to mouse by a recombinant antibody. <i>Annals of Clinical and Translational Neurology</i> , 2017 , 4, 768-783	5.3	65
254	Gut-CNS-Axis as Possibility to Modulate Inflammatory Disease Activity-Implications for Multiple Sclerosis. <i>International Journal of Molecular Sciences</i> , 2017 , 18,	6.3	21
253	An Enigmatic Case of Acute Mercury Poisoning: Clinical, Immunological Findings and Platelet Function. <i>Frontiers in Neurology</i> , 2017 , 8, 517	4.1	4
252	Cortex Parcellation Associated Whole White Matter Parcellation in Individual Subjects. <i>Frontiers in Human Neuroscience</i> , 2017 , 11, 352	3.3	5
251	Liver X receptor activation promotes differentiation of regulatory T cells. <i>PLoS ONE</i> , 2017 , 12, e0184985	3.7	30
250	Implications of dietary salt intake for multiple sclerosis pathogenesis. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 133-9	5	18
249	A novel automated segmentation method for retinal layers in OCT images proves retinal degeneration after optic neuritis. <i>British Journal of Ophthalmology</i> , 2016 , 100, 484-90	5.5	9
248	Evidence for early, non-lesional cerebellar damage in patients with multiple sclerosis: DTI measures correlate with disability, atrophy, and disease duration. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 73-84	5	35
247	CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients. <i>Neurology</i> , 2016 , 87, 958-9	6.5	6
246	Shared neural correlates of limb apraxia in early stages of Alzheimer's dementia and behavioural variant frontotemporal dementia. <i>Cortex</i> , 2016 , 84, 1-14	3.8	15
245	The potassium channels TASK2 and TREK1 regulate functional differentiation of murine skeletal muscle cells. <i>American Journal of Physiology - Cell Physiology</i> , 2016 , 311, C583-C595	5.4	12
244	Diagnostic criteria for Susac syndrome. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016 , 87, 1287-1295	13.0	
243	Imaging matrix metalloproteinase activity in multiple sclerosis as a specific marker of leukocyte penetration of the blood-brain barrier. <i>Science Translational Medicine</i> , 2016 , 8, 364ra152	17.5	68
242	Prothrombin and factor X are elevated in multiple sclerosis patients. <i>Annals of Neurology</i> , 2016 , 80, 946-951	9.1	24
241	Melanocortin-1 receptor activation is neuroprotective in mouse models of neuroinflammatory disease. <i>Science Translational Medicine</i> , 2016 , 8, 362ra146	17.5	30
240	CD62L test at 2 years of natalizumab predicts progressive multifocal leukoencephalopathy. <i>Neurology</i> , 2016 , 87, 2491-2494	6.5	17

239	Acute cholecystitis during treatment with alemtuzumab in 3 patients with RRMS. <i>Neurology</i> , 2016 , 87, 2380-2381	6.5	11
238	Computed tomography-based quantification of lesion water uptake identifies patients within 4.5 hours of stroke onset: A multicenter observational study. <i>Annals of Neurology</i> , 2016 , 80, 924-934	9.4	55
237	Alemtuzumab treatment alters circulating innate immune cells in multiple sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016 , 3, e289	9.1	62
236	Novel multiple sclerosis susceptibility loci implicated in epigenetic regulation. <i>Science Advances</i> , 2016 , 2, e1501678	14.3	75
235	Leitlinie Dermatomyositis –Auszug aus der interdisziplinären S2k-Leitlinie zu Myositissyndromen der deutschen Gesellschaft für Neurologie. <i>JDDG - Journal of the German Society of Dermatology</i> , 2016 , 14, e1-e20	1.2	
234	NMO-Spektrum-Erkrankungen. <i>InFo Neurologie & Psychiatrie</i> , 2016 , 18, 39-51	0	
233	Guidelines on dermatomyositis—excerpt from the interdisciplinary S2k guidelines on myositis syndromes by the German Society of Neurology. <i>JDDG - Journal of the German Society of Dermatology</i> , 2016 , 14, 321-38	1.2	33
232	Dimethyl fumarate treatment alters circulating T helper cell subsets in multiple sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016 , 3, e183	9.1	93
231	Neuroimmunotherapies Targeting T Cells: From Pathophysiology to Therapeutic Applications. <i>Neurotherapeutics</i> , 2016 , 13, 4-19	6.4	17
230	Sodium chloride promotes pro-inflammatory macrophage polarization thereby aggravating CNS autoimmunity. <i>Journal of Autoimmunity</i> , 2016 , 67, 90-101	15.5	97
229	Immunoabsorption therapy in autoimmune encephalitides. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016 , 3, e207	9.1	58
228	Simultaneous early-onset immune thrombocytopenia and autoimmune thyroid disease following alemtuzumab treatment in relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 1235-41	5	14
227	Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society. <i>Journal of Neurology</i> , 2016 , 263, 1473-94	5.5	104
226	Therapy with natalizumab is associated with high JCV seroconversion and rising JCV index values. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016 , 3, e195	9.1	52
225	CD4(+)HLA-G(+) regulatory T cells: Molecular signature and pathophysiological relevance. <i>Human Immunology</i> , 2016 , 77, 727-33	2.3	23
224	Highlights from the 31st ECTRIMS congress - Barcelona 2015. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 7-10	5	11
223	CD4+ T effector memory cell dysfunction is associated with the accumulation of granulocytic myeloid-derived suppressor cells in glioblastoma patients. <i>Neuro-Oncology</i> , 2016 , 18, 807-18	1	90
222	PML risk stratification using anti-JCV antibody index and L-selectin. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 1048-60	5	57

221	Dementia Apraxia Test (DATE): A Brief Tool to Differentiate Behavioral Variant Frontotemporal Dementia from Alzheimer's Dementia Based on Apraxia Profiles. <i>Journal of Alzheimer's Disease</i> , 2016 , 49, 593-605	4.3	26
220	Therapie der Multiplen Sklerose 2016 , 55-93		1
219	Dichoptic Metacontrast Masking Functions to Infer Transmission Delay in Optic Neuritis. <i>PLoS ONE</i> , 2016 , 11, e0163375	3.7	
218	Regulatory Functions of Natural Killer Cells in Multiple Sclerosis. <i>Frontiers in Immunology</i> , 2016 , 7, 606	8.4	58
217	Epoch Analysis of On-Treatment Disability Progression Events over Time in the Tysabri Observational Program (TOP). <i>PLoS ONE</i> , 2016 , 11, e0144834	3.7	5
216	Evidence of a pathogenic role for CD8(+) T cells in anti-GABAB receptor limbic encephalitis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016 , 3, e232	9.1	32
215	Early silent microstructural degeneration and atrophy of the thalamocortical network in multiple sclerosis. <i>Human Brain Mapping</i> , 2016 , 37, 1866-79	5.9	37
214	CD8(+) T-cell pathogenicity in Rasmussen encephalitis elucidated by large-scale T-cell receptor sequencing. <i>Nature Communications</i> , 2016 , 7, 11153	17.4	64
213	Blood coagulation factor XII drives adaptive immunity during neuroinflammation via CD87-mediated modulation of dendritic cells. <i>Nature Communications</i> , 2016 , 7, 11626	17.4	77
212	ALAIN01--Alemtuzumab in autoimmune inflammatory neurodegeneration: mechanisms of action and neuroprotective potential. <i>BMC Neurology</i> , 2016 , 16, 34	3.1	11
211	Comparative efficacy of first-line natalizumab vs IFN- β or glatiramer acetate in relapsing MS. <i>Neurology: Clinical Practice</i> , 2016 , 6, 102-115	1.7	21
210	Failed, interrupted and inconclusive trials on relapsing multiple sclerosis treatment: update 2010-2015. <i>Expert Review of Neurotherapeutics</i> , 2016 , 16, 689-700	4.3	11
209	Impaired NK-mediated regulation of T-cell activity in multiple sclerosis is reconstituted by IL-2 receptor modulation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016 , 113, E2973-82	11.5	98
208	B7-H1 shapes T-cell-mediated brain endothelial cell dysfunction and regional encephalitogenicity in spontaneous CNS autoimmunity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016 , 113, E6182-E6191	11.5	18
207	The farnesoid-X-receptor in myeloid cells controls CNS autoimmunity in an IL-10-dependent fashion. <i>Acta Neuropathologica</i> , 2016 , 132, 413-31	14.3	17
206	Therapeutic uses of anti- β -integrin (anti-VLA-4) antibodies in multiple sclerosis. <i>International Immunology</i> , 2015 , 27, 47-53	4.9	37
205	Long-term efficacy of alemtuzumab in polymyositis. <i>Rheumatology</i> , 2015 , 54, 560-2	3.9	11
204	Optimizing therapy early in multiple sclerosis: An evidence-based view. <i>Multiple Sclerosis and Related Disorders</i> , 2015 , 4, 460-469	4	77

203	Randomized study of teriflunomide effects on immune responses to neoantigen and recall antigens. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015 , 2, e70	9.1	41
202	Recovery of thalamic microstructural damage after Shiga toxin 2-associated hemolytic-uremic syndrome. <i>Journal of the Neurological Sciences</i> , 2015 , 356, 175-83	3.2	4
201	Gaps Between Aims and Achievements in Therapeutic Modification of Neuronal Damage ("Neuroprotection"). <i>Neurotherapeutics</i> , 2015 , 12, 449-54	6.4	23
200	FTY720 (fingolimod) treatment tips the balance towards less immunogenic antigen-presenting cells in patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 1811-22	5	27
199	Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2015 , 373, 1418-28	59.2	203
198	Nrf2 and beyond: deciphering the mode of action of fumarates in the inflamed central nervous system. <i>Acta Neuropathologica</i> , 2015 , 130, 297-8	14.3	3
197	B7-H1 Selectively Controls TH17 Differentiation and Central Nervous System Autoimmunity via a Novel Non-PD-1-Mediated Pathway. <i>Journal of Immunology</i> , 2015 , 195, 3584-95	5.3	9
196	Assessment of immune functions and MRI disease activity in relapsing-remitting multiple sclerosis patients switching from natalizumab to fingolimod (ToFingo-Successor). <i>BMC Neurology</i> , 2015 , 15, 96	3.1	5
195	Clinical relevance of specific T-cell activation in the blood and cerebrospinal fluid of patients with mild Alzheimer's disease. <i>Neurobiology of Aging</i> , 2015 , 36, 81-9	5.6	86
194	Apraxia profile differentiates behavioural variant frontotemporal from Alzheimer's dementia in mild disease stages. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015 , 86, 809-15	5.5	16
193	Fingolimod treatment promotes regulatory phenotype and function of B cells. <i>Annals of Clinical and Translational Neurology</i> , 2015 , 2, 119-30	5.3	68
192	Comparative efficacy of switching to natalizumab in active multiple sclerosis. <i>Annals of Clinical and Translational Neurology</i> , 2015 , 2, 373-87	5.3	42
191	The two-pore domain K2 P channel TASK2 drives human NK-cell proliferation and cytolytic function. <i>European Journal of Immunology</i> , 2015 , 45, 2602-14	6.1	8
190	Successful Replication of GWAS Hits for Multiple Sclerosis in 10,000 Germans Using the Exome Array. <i>Genetic Epidemiology</i> , 2015 , 39, 601-8	2.6	9
189	Interferon-Beta Therapy of Multiple Sclerosis Patients Improves the Responsiveness of T Cells for Immune Suppression by Regulatory T Cells. <i>International Journal of Molecular Sciences</i> , 2015 , 16, 16330-46	6.3	18
188	Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond. <i>International Journal of Molecular Sciences</i> , 2015 , 16, 16414-39	6.3	115
187	Murine K2P5.1 Deficiency Has No Impact on Autoimmune Neuroinflammation due to Compensatory K2P3.1- and KV1.3-Dependent Mechanisms. <i>International Journal of Molecular Sciences</i> , 2015 , 16, 16880-96	6.3	3
186	Early and Degressive Putamen Atrophy in Multiple Sclerosis. <i>International Journal of Molecular Sciences</i> , 2015 , 16, 23195-209	6.3	19

185	Treating a GAD65 Antibody-Associated Limbic Encephalitis with Basiliximab: A Case Study. <i>Frontiers in Neurology</i> , 2015 , 6, 167	4.1	23
184	Impaired Autonomic Responses to Emotional Stimuli in Autoimmune Limbic Encephalitis. <i>Frontiers in Neurology</i> , 2015 , 6, 250	4.1	4
183	Pharmacological Approaches to Delaying Disability Progression in Patients with Multiple Sclerosis. <i>Drugs</i> , 2015 , 75, 947-77	12.1	26
182	Neurocognitive decline in HIV patients is associated with ongoing T-cell activation in the cerebrospinal fluid. <i>Annals of Clinical and Translational Neurology</i> , 2015 , 2, 906-19	5.3	29
181	A human post-mortem brain model for the standardization of multi-centre MRI studies. <i>NeuroImage</i> , 2015 , 110, 11-21	7.9	25
180	Fingolimod does not impair T-cell release from the thymus and beneficially affects Treg function in patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 1521-32	5	18
179	CD28 superagonist-mediated boost of regulatory T cells increases thrombo-inflammation and ischemic neurodegeneration during the acute phase of experimental stroke. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2015 , 35, 6-10	7.3	53
178	The NKG2D-IL-15 signaling pathway contributes to T-cell mediated pathology in inflammatory myopathies. <i>Oncotarget</i> , 2015 , 6, 43230-43	3.3	10
177	Teriflunomide and its mechanism of action in multiple sclerosis. <i>Drugs</i> , 2014 , 74, 659-74	12.1	202
176	Ultraviolet B light attenuates the systemic immune response in central nervous system autoimmunity. <i>Annals of Neurology</i> , 2014 , 75, 739-58	9.4	85
175	Phospholipase D1 mediates lymphocyte adhesion and migration in experimental autoimmune encephalomyelitis. <i>European Journal of Immunology</i> , 2014 , 44, 2295-305	6.1	18
174	Clinical relevance of brain volume measures in multiple sclerosis. <i>CNS Drugs</i> , 2014 , 28, 147-56	6.7	201
173	The neuroinflammation biobank in the Department of Neurology, University Hospital Muenster, Germany. <i>Biopreservation and Biobanking</i> , 2014 , 12, 74-5	2.1	2
172	Specific aspects of modern life for people with multiple sclerosis: considerations for the practitioner. <i>Therapeutic Advances in Neurological Disorders</i> , 2014 , 7, 137-49	6.6	8
171	Increased cortical curvature reflects white matter atrophy in individual patients with early multiple sclerosis. <i>NeuroImage: Clinical</i> , 2014 , 6, 475-87	5.3	25
170	Effects of glatiramer acetate in a spontaneous model of autoimmune neuroinflammation. <i>American Journal of Pathology</i> , 2014 , 184, 2056-65	5.8	7
169	Blocking of α 4 integrin does not protect from acute ischemic stroke in mice. <i>Stroke</i> , 2014 , 45, 1799-806	6.7	66
168	Myelin oligodendrocyte glycoprotein (MOG35-55) induced experimental autoimmune encephalomyelitis (EAE) in C57BL/6 mice. <i>Journal of Visualized Experiments</i> , 2014 ,	1.6	79

167	Specific loss of cellular L-selectin on CD4(+) T cells is associated with progressive multifocal leukoencephalopathy development during HIV infection. <i>Aids</i> , 2014 , 28, 793-5	3.5	19
166	Programmed cell death-1 deficiency exacerbates T cell activation and atherogenesis despite expansion of regulatory T cells in atherosclerosis-prone mice. <i>PLoS ONE</i> , 2014 , 9, e93280	3.7	59
165	FoxP3+ regulatory T cells determine disease severity in rodent models of inflammatory neuropathies. <i>PLoS ONE</i> , 2014 , 9, e108756	3.7	15
164	CD3-positive B cells: a storage-dependent phenomenon. <i>PLoS ONE</i> , 2014 , 9, e110138	3.7	3
163	Effects of blood transportation on human peripheral mononuclear cell yield, phenotype and function: implications for immune cell biobanking. <i>PLoS ONE</i> , 2014 , 9, e115920	3.7	33
162	Human CD4+ HLA-G+ regulatory T cells are potent suppressors of graft-versus-host disease in vivo. <i>FASEB Journal</i> , 2014 , 28, 3435-45	0.9	41
161	VLA-4 blockade promotes differential routes into human CNS involving PSGL-1 rolling of T cells and MCAM-adhesion of TH17 cells. <i>Journal of Experimental Medicine</i> , 2014 , 211, 1833-46	16.6	96
160	Response to letter regarding article, "blocking of α 4 integrin does not protect from acute ischemic stroke in mice". <i>Stroke</i> , 2014 , 45, e196	6.7	1
159	Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014 , 85, 1190-7	5.5	130
158	Immunophenotyping of cerebrospinal fluid cells in multiple sclerosis: in search of biomarkers. <i>JAMA Neurology</i> , 2014 , 71, 905-12	17.2	34
157	Monoclonal antibodies in neuroinflammatory diseases. <i>Expert Opinion on Biological Therapy</i> , 2013 , 13, 831-46	5.4	12
156	Fine-tuning of regulatory T cell function: the role of calcium signals and naive regulatory T cells for regulatory T cell deficiency in multiple sclerosis. <i>Journal of Immunology</i> , 2013 , 190, 4965-70	5.3	40
155	Excitotoxic neuronal cell death during an oligodendrocyte-directed CD8+ T cell attack in the CNS gray matter. <i>Journal of Neuroinflammation</i> , 2013 , 10, 121	10.1	14
154	Endothelial TWIK-related potassium channel-1 (TREK1) regulates immune-cell trafficking into the CNS. <i>Nature Medicine</i> , 2013 , 19, 1161-5	50.5	112
153	4-Aminopyridine ameliorates mobility but not disease course in an animal model of multiple sclerosis. <i>Experimental Neurology</i> , 2013 , 248, 62-71	5.7	19
152	Regulatory T cells are strong promoters of acute ischemic stroke in mice by inducing dysfunction of the cerebral microvasculature. <i>Blood</i> , 2013 , 121, 679-91	2.2	240
151	DTI detects water diffusion abnormalities in the thalamus that correlate with an extremity pain episode in a patient with multiple sclerosis. <i>NeuroImage: Clinical</i> , 2013 , 2, 258-62	5.3	26
150	Neurons as targets for T cells in the nervous system. <i>Trends in Neurosciences</i> , 2013 , 36, 315-24	13.3	73

149	Paraneoplastic and non-paraneoplastic autoimmunity to neurons in the central nervous system. <i>Journal of Neurology</i> , 2013 , 260, 1215-33	5.5	36
148	Modulation of IL-2R β with daclizumab for treatment of multiple sclerosis. <i>Nature Reviews Neurology</i> , 2013 , 9, 394-404	15	65
147	Identification of two-pore domain potassium channels as potent modulators of osmotic volume regulation in human T lymphocytes. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2013 , 1828, 699-707	3.8	18
146	Con: Regulatory T cells are protective in ischemic stroke. <i>Stroke</i> , 2013 , 44, e87-8	6.7	17
145	An assay to quantify species-specific anti-JC virus antibody levels in MS patients. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 1137-44	5	18
144	L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients. <i>Neurology</i> , 2013 , 81, 865-71	6.5	127
143	Rasmussen encephalitis treated with natalizumab. <i>Neurology</i> , 2013 , 81, 395-7	6.5	54
142	Dendritic cell vaccination in autoimmune disease. <i>Current Opinion in Rheumatology</i> , 2013 , 25, 268-74	5.3	27
141	Multiple sclerosis: reprogramming the immune repertoire with alemtuzumab in MS. <i>Nature Reviews Neurology</i> , 2013 , 9, 125-6	15	42
140	Identification of inflammatory neuronal injury and prevention of neuronal damage in multiple sclerosis: hope for novel therapies?. <i>JAMA Neurology</i> , 2013 , 70, 1569-74	17.2	25
139	Thalamic involvement in patients with neurologic impairment due to Shiga toxin 2. <i>Annals of Neurology</i> , 2013 , 73, 419-29	9.4	9
138	Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 1533-8	5	79
137	CD4+NKG2D+ T cells exhibit enhanced migratory and encephalitogenic properties in neuroinflammation. <i>PLoS ONE</i> , 2013 , 8, e81455	3.7	21
136	Kinetics of IL-6 production defines T effector cell responsiveness to regulatory T cells in multiple sclerosis. <i>PLoS ONE</i> , 2013 , 8, e77634	3.7	34
135	CD4(+) CD25(+) FoxP3(+) regulatory T cells suppress cytotoxicity of CD8(+) effector T cells: implications for their capacity to limit inflammatory central nervous system damage at the parenchymal level. <i>Journal of Neuroinflammation</i> , 2012 , 9, 41	10.1	18
134	Pathology of immune reconstitution inflammatory syndrome in multiple sclerosis with natalizumab-associated progressive multifocal leukoencephalopathy. <i>Acta Neuropathologica</i> , 2012 , 123, 235-45	14.3	89
133	Dendritic cells ameliorate autoimmunity in the CNS by controlling the homeostasis of PD-1 receptor(+) regulatory T cells. <i>Immunity</i> , 2012 , 37, 264-75	32.3	154
132	The TASK1 channel inhibitor A293 shows efficacy in a mouse model of multiple sclerosis. <i>Experimental Neurology</i> , 2012 , 238, 149-55	5.7	32

131	CD4(+) T cells predominate in cerebrospinal fluid and leptomeningeal and parenchymal infiltrates in cerebral amyloid β -related angiitis. <i>Archives of Neurology</i> , 2012 , 69, 773-7		28
130	Licensing of myeloid cells promotes central nervous system autoimmunity and is controlled by peroxisome proliferator-activated receptor γ . <i>Brain</i> , 2012 , 135, 1586-605	11.2	42
129	Cytotoxic CD8+ T cells and CD138+ plasma cells prevail in cerebrospinal fluid in non-paraneoplastic cerebellar ataxia with contactin-associated protein-2 antibodies. <i>Journal of Neuroinflammation</i> , 2012 , 9, 160	10.1	9
128	Fulfilling the dream: tolerogenic dendritic cells to treat multiple sclerosis. <i>European Journal of Immunology</i> , 2012 , 42, 569-72	6.1	26
127	Immune mechanisms of new therapeutic strategies in multiple sclerosis-A focus on alemtuzumab. <i>Clinical Immunology</i> , 2012 , 142, 25-30	9	52
126	Anti-JC-virus antibody prevalence in a German MS cohort. <i>Multiple Sclerosis Journal</i> , 2012 , 18, 1054-5	5	13
125	Immune mechanisms of stroke. <i>Current Opinion in Neurology</i> , 2012 , 25, 334-40	7.1	56
124	Neuron-directed autoimmunity in the central nervous system: entities, mechanisms, diagnostic clues, and therapeutic options. <i>Current Opinion in Neurology</i> , 2012 , 25, 341-8	7.1	16
123	Immunological and clinical consequences of treating a patient with natalizumab. <i>Multiple Sclerosis Journal</i> , 2012 , 18, 335-44	5	35
122	Immune therapy of multiple sclerosis--future strategies. <i>Current Pharmaceutical Design</i> , 2012 , 18, 4489-97	3	22
121	TRPM2 cation channels modulate T cell effector functions and contribute to autoimmune CNS inflammation. <i>PLoS ONE</i> , 2012 , 7, e47617	3.7	51
120	Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). <i>Arthritis Research and Therapy</i> , 2011 , 13, R75	5.7	136
119	Expression of K2P5.1 potassium channels on CD4+ T lymphocytes correlates with disease activity in rheumatoid arthritis patients. <i>Arthritis Research and Therapy</i> , 2011 , 13, R21	5.7	22
118	Volume regulation of murine T lymphocytes relies on voltage-dependent and two-pore domain potassium channels. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 2011 , 1808, 2036-44	3.8	31
117	Blockade of the kinin receptor B1 protects from autoimmune CNS disease by reducing leukocyte trafficking. <i>Journal of Autoimmunity</i> , 2011 , 36, 106-14	15.5	64
116	Active immunization with proteolipid protein (190-209) induces ascending paralyzing experimental autoimmune encephalomyelitis in C3H/HeJ mice. <i>Journal of Immunological Methods</i> , 2011 , 367, 27-32	2.5	4
115	Transforming multiple sclerosis trials into practical reality. <i>Lancet Neurology</i> , 2011 , 10, 493-4	24.1	2
114	Ion channels in autoimmune neurodegeneration. <i>FEBS Letters</i> , 2011 , 585, 3836-42	3.8	24

113	Janus head: the dual role of HLA-G in CNS immunity. <i>Cellular and Molecular Life Sciences</i> , 2011 , 68, 407-160.3	11
112	Natalizumab restores evoked potential abnormalities in patients with relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2011 , 17, 198-203	5 24
111	From the background to the spotlight: TASK channels in pathological conditions. <i>Brain Pathology</i> , 2010 , 20, 999-1009	6 59
110	Identification of targets and new developments in the treatment of multiple sclerosis--focus on cladribine. <i>Drug Design, Development and Therapy</i> , 2010 , 4, 117-26	4.4 5
109	Lessons from the Past and Future Approaches for Immunologic Therapies in Multiple Sclerosis. <i>Blue Books of Neurology</i> , 2010 , 388-426	
108	An imbalance of two functionally and phenotypically different subsets of plasmacytoid dendritic cells characterizes the dysfunctional immune regulation in multiple sclerosis. <i>Journal of Immunology</i> , 2010 , 184, 5368-74	5.3 52
107	Stromal interaction molecules 1 and 2 are key regulators of autoreactive T cell activation in murine autoimmune central nervous system inflammation. <i>Journal of Immunology</i> , 2010 , 184, 1536-42	5.3 84
106	Postpartum disease activity and breastfeeding in multiple sclerosis revisited. <i>Neurology</i> , 2010 , 75, 392-36.5	4
105	Deficiency of the negative immune regulator B7-H1 enhances inflammation and neuropathic pain after chronic constriction injury of mouse sciatic nerve. <i>Experimental Neurology</i> , 2010 , 222, 153-60	5.7 22
104	Glatiramer acetate attenuates pro-inflammatory T cell responses but does not directly protect neurons from inflammatory cell death. <i>American Journal of Pathology</i> , 2010 , 177, 3051-60	5.8 8
103	Therapeutic approaches to multiple sclerosis: an update on failed, interrupted, or inconclusive trials of immunomodulatory treatment strategies. <i>BioDrugs</i> , 2010 , 24, 249-74	7.9 20
102	Therapeutic approaches to multiple sclerosis: an update on failed, interrupted, or inconclusive trials of neuroprotective and alternative treatment strategies. <i>BioDrugs</i> , 2010 , 24, 317-30	7.9 18
101	Collateral neuronal apoptosis in CNS gray matter during an oligodendrocyte-directed CD8(+) T cell attack. <i>Glia</i> , 2010 , 58, 469-80	9 24
100	Early detrimental T-cell effects in experimental cerebral ischemia are neither related to adaptive immunity nor thrombus formation. <i>Blood</i> , 2010 , 115, 3835-42	2.2 267
99	The role of dendritic cells in CNS autoimmunity. <i>Journal of Molecular Medicine</i> , 2010 , 88, 535-44	5.5 65
98	Active immunization induces toxicity of diphtheria toxin in diphtheria resistant mice--implications for neuroinflammatory models. <i>Journal of Immunological Methods</i> , 2010 , 354, 80-4	2.5 18
97	FOXP3+ T regulatory cells in idiopathic inflammatory myopathies. <i>Journal of Neuroimmunology</i> , 2010 , 225, 137-42	3.5 44
96	Mouse Schwann cells activate MHC class I and II restricted T-cell responses, but require external peptide processing for MHC class II presentation. <i>Neurobiology of Disease</i> , 2010 , 37, 483-90	7.5 25

95	Lack of evidence for a pathogenic role of T-lymphocytes in an animal model for Charcot-Marie-Tooth disease 1A. <i>Neurobiology of Disease</i> , 2010 , 38, 78-84	7.5	14
94	Expression of antigen processing and presenting molecules by Schwann cells in inflammatory neuropathies. <i>Glia</i> , 2010 , 58, 80-92	9	45
93	Regulatory T cells exhibit enhanced migratory characteristics, a feature impaired in patients with multiple sclerosis. <i>European Journal of Immunology</i> , 2010 , 40, 3581-90	6.1	47
92	Upregulation of K2P5.1 potassium channels in multiple sclerosis. <i>Annals of Neurology</i> , 2010 , 68, 58-69	9.4	51
91	Two pore domain potassium channels in cerebral ischemia: a focus on K2P9.1 (TASK3, KCNK9). <i>Experimental & Translational Stroke Medicine</i> , 2010 , 2, 14		17
90	B7-H1-deficiency enhances the potential of tolerogenic dendritic cells by activating CD1d-restricted type II NKT cells. <i>PLoS ONE</i> , 2010 , 5, e10800	3.7	21
89	Temporal pattern of ICAM-1 mediated regulatory T cell recruitment to sites of inflammation in adoptive transfer model of multiple sclerosis. <i>PLoS ONE</i> , 2010 , 5, e15478	3.7	19
88	PD-1 regulates neural damage in oligodendroglia-induced inflammation. <i>PLoS ONE</i> , 2009 , 4, e4405	3.7	16
87	CD8+ T cells and neuronal damage: direct and collateral mechanisms of cytotoxicity and impaired electrical excitability. <i>FASEB Journal</i> , 2009 , 23, 3659-73	0.9	60
86	T cell suppression by naturally occurring HLA-G-expressing regulatory CD4+ T cells is IL-10-dependent and reversible. <i>Journal of Leukocyte Biology</i> , 2009 , 86, 273-81	6.5	64
85	Cytotoxic CD8+ T cell-neuron interactions: perforin-dependent electrical silencing precedes but is not causally linked to neuronal cell death. <i>Journal of Neuroscience</i> , 2009 , 29, 15397-409	6.6	69
84	CD8+ T-cell clones dominate brain infiltrates in Rasmussen encephalitis and persist in the periphery. <i>Brain</i> , 2009 , 132, 1236-46	11.2	107
83	TASK1 modulates inflammation and neurodegeneration in autoimmune inflammation of the central nervous system. <i>Brain</i> , 2009 , 132, 2501-16	11.2	81
82	Iatrogenic immunosuppression with biologics in MS: expecting the unexpected?. <i>Neurology</i> , 2009 , 73, 1346-7	6.5	9
81	Antigen-specific blockade of lethal CD8 T-cell mediated autoimmunity in a mouse model of multiple sclerosis. <i>Journal of Immunology</i> , 2009 , 182, 6569-75	5.3	12
80	Intracerebral dendritic cells critically modulate encephalitogenic versus regulatory immune responses in the CNS. <i>Journal of Neuroscience</i> , 2009 , 29, 140-52	6.6	61
79	The neuroprotective impact of the leak potassium channel TASK1 on stroke development in mice. <i>Neurobiology of Disease</i> , 2009 , 33, 1-11	7.5	44
78	The co-inhibitory molecule PD-1 modulates disease severity in a model for an inherited, demyelinating neuropathy. <i>Neurobiology of Disease</i> , 2009 , 33, 96-103	7.5	13

77	Intercellular exchanges of membrane fragments (trocytosis) between human muscle cells and immune cells: a potential mechanism for the modulation of muscular immune responses. <i>Journal of Neuroimmunology</i> , 2009 , 209, 131-8	3.5	19
76	Current status on B-cell depletion therapy in autoimmune diseases other than rheumatoid arthritis. <i>Autoimmunity Reviews</i> , 2009 , 9, 82-9	13.6	54
75	Specific central nervous system recruitment of HLA-G(+) regulatory T cells in multiple sclerosis. <i>Annals of Neurology</i> , 2009 , 66, 171-83	9.4	60
74	The level of B7 homologue 1 expression on brain DC is decisive for CD8 Treg cell recruitment into the CNS during EAE. <i>European Journal of Immunology</i> , 2009 , 39, 1536-43	6.1	22
73	Comment on "Functional consequences of Kv1.3 ion channel rearrangement into the immunological synapse". <i>Immunology Letters</i> , 2009 , 125, 156-7	4.1	3
72	The future of multiple sclerosis therapy. <i>Pharmacological Research</i> , 2009 , 60, 207-11	10.2	18
71	Multiple sclerosis therapeutics: unexpected outcomes clouding undisputed successes. <i>Neurology</i> , 2009 , 72, 1008-15	6.5	56
70	Accelerated course of experimental autoimmune encephalomyelitis in PD-1-deficient central nervous system myelin mutants. <i>American Journal of Pathology</i> , 2009 , 174, 2290-9	5.8	30
69	Collateral bystander damage by myelin-directed CD8+ T cells causes axonal loss. <i>American Journal of Pathology</i> , 2009 , 175, 1160-6	5.8	65
68	Immunotherapy of multiple sclerosis. <i>Acta Neuropsychiatrica</i> , 2009 , 21 Suppl 2, 27-34	3.9	1
67	CNS inflammation and neuronal degeneration is aggravated by impaired CD200-CD200R-mediated macrophage silencing. <i>Journal of Neuroimmunology</i> , 2008 , 194, 62-9	3.5	82
66	Human myoblasts modulate the function of antigen-presenting cells. <i>Journal of Neuroimmunology</i> , 2008 , 200, 62-70	3.5	11
65	Pharmacological treatment of early multiple sclerosis. <i>Drugs</i> , 2008 , 68, 73-83	12.1	36
64	The role of regulatory T cells in multiple sclerosis. <i>Nature Clinical Practice Neurology</i> , 2008 , 4, 384-98		159
63	The role of CD8 suppressors versus destructors in autoimmune central nervous system inflammation. <i>Human Immunology</i> , 2008 , 69, 797-804	2.3	34
62	Altered neuronal expression of TASK1 and TASK3 potassium channels in rodent and human autoimmune CNS inflammation. <i>Neuroscience Letters</i> , 2008 , 446, 133-8	3.3	12
61	TWIK-related acid-sensitive K+ channel 1 (TASK1) and TASK3 critically influence T lymphocyte effector functions. <i>Journal of Biological Chemistry</i> , 2008 , 283, 14559-70	5.4	80
60	Detrimental contribution of the immuno-inhibitor B7-H1 to rabies virus encephalitis. <i>Journal of Immunology</i> , 2008 , 180, 7506-15	5.3	76

59	A beta-lactam antibiotic dampens excitotoxic inflammatory CNS damage in a mouse model of multiple sclerosis. <i>PLoS ONE</i> , 2008 , 3, e3149	3.7	68
58	Effects of natalizumab treatment on Foxp3+ T regulatory cells. <i>PLoS ONE</i> , 2008 , 3, e3319	3.7	41
57	The two-pore domain potassium channel TASK3 functionally impacts glioma cell death. <i>Journal of Neuro-Oncology</i> , 2008 , 87, 263-70	4.8	29
56	Immunomodulatory treatment strategies in multiple sclerosis. <i>Journal of Neurology</i> , 2008 , 255 Suppl 6, 15-21	5.5	23
55	The metalloproteinase-disintegrin ADAM10 is exclusively expressed by type I muscle fibers. <i>Muscle and Nerve</i> , 2008 , 38, 1049-51	3.4	2
54	B7-H1 restricts neuroantigen-specific T cell responses and confines inflammatory CNS damage: implications for the lesion pathogenesis of multiple sclerosis. <i>European Journal of Immunology</i> , 2008 , 38, 1734-44	6.1	60
53	Human muscle cells express the costimulatory molecule B7-H3, which modulates muscle-immune interactions. <i>Arthritis and Rheumatism</i> , 2008 , 58, 3600-8		15
52	Idiopathic inflammatory myopathies: current and future therapeutic options. <i>Neurotherapeutics</i> , 2008 , 5, 548-57	6.4	16
51	Expression of Molecules Involved in Fetal-Maternal Tolerance Allows Human Mesenchymal Stem Cells to Engraft at High Levels across Immunologic Barriers. <i>Blood</i> , 2008 , 112, 3480-3480	2.2	2
50	Frequency of regulatory T cells is not affected by transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. <i>Open Rheumatology Journal</i> , 2008 , 2, 81-8	0.2	27
49	The trials and errors in MS therapy. <i>International MS Journal</i> , 2008 , 15, 79-90		7
48	Modulation of T-effector function by imatinib at the level of cytokine secretion. <i>Experimental Hematology</i> , 2007 , 35, 1266-71	3.1	30
47	Immune-refractory cancers and their little helpers--an extended role for immunetolerogenic MHC molecules HLA-G and HLA-E?. <i>Seminars in Cancer Biology</i> , 2007 , 17, 459-68	12.7	44
46	The cell-specific expression of metalloproteinase-disintegrins (ADAMs) in inflammatory myopathies. <i>Neurobiology of Disease</i> , 2007 , 25, 665-74	7.5	31
45	Postpartum-activation of multiple sclerosis is associated with down-regulation of tolerogenic HLA-G. <i>Journal of Neuroimmunology</i> , 2007 , 187, 205-11	3.5	39
44	WHO grade associated downregulation of MHC class I antigen-processing machinery components in human astrocytomas: does it reflect a potential immune escape mechanism?. <i>Acta Neuropathologica</i> , 2007 , 114, 111-9	14.3	50
43	Treatment of active secondary progressive multiple sclerosis with treosulfan. <i>Journal of Neurology</i> , 2007 , 254, 884-9	5.5	20
42	Multiple sclerosis therapy: an update on recently finished trials. <i>Journal of Neurology</i> , 2007 , 254, 1473-90	5.5	5

41	HLA-G expression defines a novel regulatory T-cell subset present in human peripheral blood and sites of inflammation. <i>Blood</i> , 2007 , 110, 568-77	2.2	149
40	Fast track to becoming a regulatory T cell: Erogocytosis of immune-tolerogenic HLA-G. <i>Blood</i> , 2007 , 109, 1796-1797	2.2	6
39	HLA-G in the nervous system. <i>Human Immunology</i> , 2007 , 68, 286-93	2.3	19
38	The genetic influence of the nonclassical MHC molecule HLA-G on multiple sclerosis. <i>Human Immunology</i> , 2007 , 68, 422-5	2.3	28
37	Oral disease-modifying treatments for multiple sclerosis: the story so far. <i>CNS Drugs</i> , 2007 , 21, 483-502	6.7	27
36	Review of Novel Immunotherapeutic Strategies for MS 2007 , 289-338		
35	The role of leukemia-derived B7-H1 (PD-L1) in tumor-T-cell interactions in humans. <i>Experimental Hematology</i> , 2006 , 34, 888-94	3.1	38
34	Multiple sclerosis: advances, excitements, disenchantments. <i>Lancet Neurology</i> , 2006 , 5, 2-3	24.1	2
33	Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro. <i>International Journal of Cancer</i> , 2006 , 119, 317-27	7.5	249
32	Immune cells contribute to myelin degeneration and axonopathic changes in mice overexpressing proteolipid protein in oligodendrocytes. <i>Journal of Neuroscience</i> , 2006 , 26, 8206-16	6.6	94
31	The contribution of TWIK-related acid-sensitive K ⁺ -containing channels to the function of dorsal lateral geniculate thalamocortical relay neurons. <i>Molecular Pharmacology</i> , 2006 , 69, 1468-76	4.3	56
30	Expression of toll-like receptors by human muscle cells in vitro and in vivo: TLR3 is highly expressed in inflammatory and HIV myopathies, mediates IL-8 release and up-regulation of NKG2D-ligands. <i>FASEB Journal</i> , 2006 , 20, 118-20	0.9	73
29	No effect of immunomodulatory therapy in focal epilepsy with positive glutamate receptor type 3-antibodies. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2006 , 15, 350-4	3.2	8
28	Expression of the immune-tolerogenic major histocompatibility molecule HLA-G in multiple sclerosis: implications for CNS immunity. <i>Brain</i> , 2005 , 128, 2689-704	11.2	137
27	Immunobiology of muscle: advances in understanding an immunological microenvironment. <i>Trends in Immunology</i> , 2005 , 26, 373-80	14.4	150
26	Diffusion abnormality in Balo's concentric sclerosis: clues for the pathogenesis. <i>European Neurology</i> , 2005 , 53, 42-4	2.1	24
25	Muscle-derived positive and negative regulators of the immune response. <i>Current Opinion in Rheumatology</i> , 2005 , 17, 714-9	5.3	22
24	Monocyte-derived HLA-G acts as a strong inhibitor of autologous CD4 T cell activation and is upregulated by interferon-beta in vitro and in vivo: rationale for the therapy of multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2005 , 159, 155-64	3.5	61

23	Multiple sclerosis: Mitoxantrone promotes differential effects on immunocompetent cells in vitro. <i>Journal of Neuroimmunology</i> , 2005 , 168, 128-37	3.5	56
22	A PD-1 polymorphism is associated with disease progression in multiple sclerosis. <i>Annals of Neurology</i> , 2005 , 58, 50-7	9.4	168
21	Microglial expression of the B7 family member B7 homolog 1 confers strong immune inhibition: implications for immune responses and autoimmunity in the CNS. <i>Journal of Neuroscience</i> , 2005 , 25, 2537-46	6.6	134
20	Antigen recognition properties of a Vgamma1.3Vdelta2-T-cell receptor from a rare variant of polymyositis. <i>Journal of Neuroimmunology</i> , 2004 , 152, 168-75	3.5	9
19	Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2004 , 155, 172-82	3.5	215
18	Disease-modifying therapies in multiple sclerosis: an update on recent and ongoing trials and future strategies. <i>Expert Opinion on Investigational Drugs</i> , 2003 , 12, 689-712	5.9	23
17	Muscle fibres and cultured muscle cells express the B7.1/2-related inducible co-stimulatory molecule, ICOSL: implications for the pathogenesis of inflammatory myopathies. <i>Brain</i> , 2003 , 126, 1026-35	11.2	101
16	The non-classical MHC molecule HLA-G protects human muscle cells from immune-mediated lysis: implications for myoblast transplantation and gene therapy. <i>Brain</i> , 2003 , 126, 176-85	11.2	76
15	Hide-and-seek in the brain: a role for HLA-G mediating immune privilege for glioma cells. <i>Seminars in Cancer Biology</i> , 2003 , 13, 343-51	12.7	34
14	Action of treosulfan in myelin-oligodendrocyte-glycoprotein-induced experimental autoimmune encephalomyelitis and human lymphocytes. <i>Journal of Neuroimmunology</i> , 2003 , 144, 28-37	3.5	24
13	Antigen processing and presentation in human muscle: cathepsin S is critical for MHC class II expression and upregulated in inflammatory myopathies. <i>Journal of Neuroimmunology</i> , 2003 , 138, 132-43	3.5	40
12	The CD28 related molecule ICOS: T cell modulation in the presence and absence of B7.1/2 and regulational expression in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2003 , 140, 177-87	3.5	9
11	Expression of the B7-related molecule ICOSL by human glioma cells in vitro and in vivo. <i>Glia</i> , 2003 , 44, 296-301	9	27
10	Express and protect yourself: the potential role of HLA-G on muscle cells and in inflammatory myopathies. <i>Human Immunology</i> , 2003 , 64, 1050-6	2.3	25
9	Human muscle cells express a B7-related molecule, B7-H1, with strong negative immune regulatory potential: a novel mechanism of counterbalancing the immune attack in idiopathic inflammatory myopathies. <i>FASEB Journal</i> , 2003 , 17, 1892-4	0.9	90
8	Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis. <i>Cancer Research</i> , 2003 , 63, 7462-7	10.1	272
7	Destruction of neurons by cytotoxic T cells: a new pathogenic mechanism in Rasmussen's encephalitis. <i>Annals of Neurology</i> , 2002 , 51, 311-8	9.4	290
6	Advances in pathogenic concepts and therapeutic agents in Rasmussen's encephalitis. <i>Expert Opinion on Investigational Drugs</i> , 2002 , 11, 981-9	5.9	17

5	An autoreactive gamma delta TCR derived from a polymyositis lesion. <i>Journal of Immunology</i> , 2002 , 169, 515-21	5-3	38
4	A functional role of HLA-G expression in human gliomas: an alternative strategy of immune escape. <i>Journal of Immunology</i> , 2002 , 168, 4772-80	5-3	277
3	Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials. <i>BioDrugs</i> , 2002 , 16, 183-200	7-9	138
2	Muscle fibers in inflammatory myopathies and cultured myoblasts express the nonclassical major histocompatibility antigen HLA-G. <i>Annals of Neurology</i> , 2000 , 48, 679-684	9-4	84
1	Integrated single cell analysis of blood and cerebrospinal fluid leukocytes in multiple sclerosis		1